

Strong growth in 2007 revenues Up 27.4% at constant USD rates to EUR 79.5 million

In EUR millions	2006	2007	Change	Change at constant USD rates
First quarter	18.3	21.2	+15.6%	+22.9%
Second quarter	16.3	20.6	+26.4%	+32.6%
Third quarter	15.1	18.3	+21.7%	+27.2%
Fourth quarter	16.5	19.4	+17.6%	+27.2%
12 months	66.2	79.5*	+20.1%	+27.4%

^{*} Including the integration of HP Botanicals on April 1, 2007.

Naturex posted full-year revenues of EUR 79.5 million in 2007, an increase of 20.1% (27.4% at constant USD rates) on 2006. Organic** growth stood at 5.8% at current USD rate and at 12.1% at constant USD rate.

Including over 12 months HP Botanicals (acquired on April 1, 2007), Chart Corporation (acquired on December 20, 2007) and Berkem's Active Ingredients division, 2007 pro-forma revenues totaled EUR 88.9 million. Revenues break down as follows: neutraceuticals 56.5%, flavoring and food processing 32.2%, pharmaceuticals 5.5% and cosmetics 2.0%. The United States represented 59.1% of revenues, Europe 24.2%, France 9.7% and Asia/Oceania 3.7%.

Outlook for 2008

Naturex will continue to broaden its sales network in 2008 with the setting up of a subsidiary in China and the opening of two sales offices, one in Germany which will also cover the Benelux countries in the first half of the year and the other in Japan in the second half of the year.

The Group intends to generate double-digit organic growth at constant USD rates in 2008.

Your contacts

NATUREX

Jacques Dikansky – President and CEO Phone.: +33 4 90 23 96 89 j.dikansky@naturex.com

ACTUS

Coralie Vogt – Financial PR Phone: +33 1 53 67 35 79 cvogt@actus.fr

NATUREX has been listed since October 1996

Eurolist by Euronext Paris, segment B - ISIN: FR0000054694

Reuters NATU.LN - Bloomberg NTRX:FP

^{**} by integrating Hammer Pharma and HP Botanicals over 12 months in 2006 and 2007.